Page 3 - Fly Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval

Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Yasuo matsuedaBusiness developmentFly pharma incWall streetOverall survivalOrphan drug designationFly pharmaDelta fly pharma

Delta-Fly Pharma, Inc is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid

United statesBritish columbiaKiyoshi eshimaYasuo matsuedaHead officeDrug administrationMd anderson cancer centerFly pharma incBranch officeDelta fly pharmaOrphan drug designationAcute myeloid leukemiaCancer centerHematologic cancer treatmentFly pharmaJapanese yen